PixarBio Corporation

60 articles about PixarBio Corporation

• PixarBio To Participate In Event Addressing Connecticut’s Opioid Epidemic

  8/30/2016

• PixarBio Announces The Opening Of The Oversubscription Of Stock Offering, And Extends Offering Close To September 9, 2016

  8/22/2016

• PixarBio Announces Public Offering To Fund Development Of NeuroRelease, A Morphine Strength, Non-Opiate/Opioid, Non-Addictive Pain Treatment

  8/8/2016

• PixarBio Announces Xi Chen, Dr. Amer Khalil, And Haining Dai Are Final Cofounders For All Public Filings

  8/3/2016

• PixarBio Ribbon Cutting Ceremony With Fort Lee New Jersey Mayor, Mark Sokolich Set For August 9, 2016

  8/2/2016

• PixarBio Announces 7-Day Neurorelease Pain, And USPTO Patent Filing For “Sprinkle On” 3-Day Neurorelease™ Pain Sterile Powder

  8/2/2016

• World Renowned Entrepreneur Laura Morse Joins PixarBio’s Board Of Directors As PixarBio Prepares For SEC Compliance

  7/11/2016

• PixarBio Promotes David Kaplan To Chief Commercial Officer, As Neurorelease A Morphine Strength Non Addictive Pain Treatment Remains On Track For 2018 Launch

  6/27/2016

• PixarBio Receives Boston Business Journal "2016 Best Places To Work" Just-In-Time For PixarBio’s Public Offering

  6/24/2016

• Massachusetts’ PixarBio Hiring at New Jersey Site to Respond to Opioid Crisis

  5/12/2016

• PixarBio Corporation Wins "2016 Best Places To Work" By The Boston Business Journal; Unique Corporate Culture Creates Inspiring And An Innovative Work Environment

  4/20/2016

• PixarBio Corporation, The Developers Of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President Of External Affairs

  3/30/2016

• PixarBio Corporation Corporation Announces FDA OPD Submission Of NeuroRelease SCI For Orphan Drug Designation For Spinal Cord Injury

  3/18/2016

• PixarBio Corporation’s NeuroRelease A Revolutionary Non Addictive Pain Treatment Draws Pain Industry Star Sales Executive David Kaplan As Global VP Of Sales & Marketing

  3/9/2016

• PixarBio Corporation’s Dr. Taunia Markvicka And Glenn Reiser To Discuss Breakthrough Data On Morphine Strength Non-Addictive Pain Treatment™ Neurorelease™ At The 2016 Congress Of Neurological Surgeons Spine Summit Held In Orlando, FL March 17-18, 2016

  3/3/2016

• PixarBio Corporation Answers The Governors' Call For Non-Opiate Pain Treatment By Expanding Salem, NH Office

  2/24/2016

• PixarBio Corporation Turns Focus To Commercialization In 2018 For NeuroRelease A Non Opiate, Non Addictive Pain Treatment, Adding Industry Sales Veteran Taunia Markvicka As Chief Commercial Officer (CCO)

  2/22/2016

• PixarBio Corporation CEO Frank Reynolds To Present Non-Opiate, Non-Addictive Pain Treatment Portfolio At The 2016 Biotech Showcase In San Francisco, CA On January 12, 2016

  1/4/2016

• PixarBio Corporation Builds Regulatory Team Adding Steven Chartier, As Vice President Of Regulatory Affairs, To Lead Non-Opiate, Non-Addictive Pain Treatment Through The U.S. FDA And European Regulatory Bodies

  12/28/2015

• PixarBio Corporation Prepares For Next Phase Of Growth, Adding Ken Stromsland As Chief Information Officer (CIO)

  12/18/2015